3657 results for «445»
3657 results
Challenging TAVI access: exploring transfemoral boundaries and mastering alternative access
20 May 2026 – From EuroPCR 2026
This session investigates the boundaries of transfemoral access for TAVI and strategies to safely extend its use. It also provides a comprehensive review of facilitated transfemoral TAVI techniques and explores alternative access options, offering critical insights for managing challenging TAVI cases.
Multi-device approach to calcified lesions
20 May 2026 – From EuroPCR 2026
Explore a multi-device strategy for tackling complex calcified coronary lesions in this session. It includes case studies on left main trifurcation stenting, resistant calcified nodules treated with orbital atherectomy, severe restenosis, and critical calcifications in challenging anatomies, showcasing advanced techniques for plaque modification and lesion management.
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
TAVI for aortic regurgitation
20 May 2026 – From EuroPCR 2026
This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
Transcatheter rescue in cardiogenic shock
20 May 2026 – From EuroPCR 2026
This session presents cutting-edge transcatheter rescue interventions in cardiogenic shock scenarios. It covers emergent valve-in-valve procedures, hybrid approaches for valvular heart disease with heart failure, management of ventricular septal rupture post-myocardial infarction, and percutaneous closure techniques for high-risk patients, emphasizing lifesaving interventional strategies.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Imaging guidance in everyday practice
20 May 2026 – From EuroPCR 2026
This session emphasizes the role of imaging guidance in everyday interventional cardiology practice. Through challenging cases involving exertional chest pain, unusual coronary anatomy, complex left ventricular access, side branch navigation, and IVUS-guided re-intervention, it underscores the critical value of advanced imaging for diagnostic clarity and procedural...
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
09 May 2023
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
EuroPCR 2026: Elixir Medical's DynamX® bioadaptor demonstrates significantly lower event rates than drug-eluting stent in long-term follow-up, including reduction in cardiovascular death
19 May 2026
Promising Safety and Efficacy Results for Supraflex Cruz in HBR Subset Analysis from FIRE Trial, with 1-Month DAPT
03 Nov 2023
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
Positive 3-year results from FIRE Trial demonstrate Supraflex Cruz’s safety and efficacy in elderly heart attack patients
26 Sep 2025
EuroPCR 2024: Late-breaking data demonstrate significant clinical advantage of Elixir Medical’s DynamX bioadaptor over standard-of-care drug-eluting stent at two years
14 May 2024
Elixir Medical’s DynamX Bioadaptor demonstrates significant improvement over contemporary drug-eluting stent in patients with acute coronary syndrome and complex lesion subsets after six months
28 Oct 2024
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
17 May 2023